The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients

被引:10
作者
Andre, Camille [1 ]
Mernissi, Touria [1 ]
Choukroun, Gabriel [1 ]
Bennis, Youssef [1 ]
Kamel, Said [1 ]
Liabeuf, Sophie [1 ]
Bodeau, Sandra [1 ]
机构
[1] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80000 Amiens, France
关键词
uremic toxin; organic anion transporter; OAT1; inhibitor; OAT3; kidney transplantation; PROTON PUMP INHIBITORS; INDOXYL SULFATE; RENAL EXCRETION; PHARMACOKINETICS; INVOLVEMENT; MORTALITY; DISEASE; ASPIRIN; SINGLE;
D O I
10.3390/toxins14010015
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The renal elimination of uremic toxins (UTs) can be potentially altered by drugs that inhibit organic anion transporters 1/3 (OAT1/OAT3). The objective of the present study was to determine whether the prescription of at least one OAT1/OAT3 inhibitor was associated with the plasma accumulation of certain UTs in kidney transplant recipients. We included 403 kidney transplant recipients. For each patient, we recorded all prescription drugs known to inhibit OAT1/OAT3. Plasma levels of four UTs (trimethylamine N-oxide (TMAO), indole acetic acid (IAA), para-cresylsulfate (pCS), and indoxylsulfate (IxS) were assayed using liquid chromatography-tandem mass spectrometry. Plasma UT levels were significantly higher among patients prescribed at least one OAT inhibitor (n = 311) than among patients not prescribed any OAT inhibitors (n = 92). Multivariate analysis revealed that after adjustment for age, estimated glomerular filtration rate (eGFR), plasma level of albumin and time since transplantation, prescription of an OAT1/OAT3 inhibitor was independently associated with the plasma accumulation of pCS (adjusted odds ratio (95% confidence interval): 2.11 (1.26; 3.61]). Our results emphasize the importance of understanding the interactions between drugs and UTs and those involving UT transporters in particular.
引用
收藏
页数:15
相关论文
共 58 条
  • [1] Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors
    Andre, Camille
    Choukroun, Gabriel
    Bennis, Youssef
    Kamel, Said
    Lemaire-Hurtel, Anne Sophie
    Masmoudi, Kamel
    Bodeau, Sandra
    Liabeuf, Sophie
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (11) : 2284 - 2292
  • [2] Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury
    Andre, Camille
    Bennis, Youssef
    Titeca-Beauport, Dimitri
    Caillard, Pauline
    Cluet, Yan
    Kamel, Said
    Choukroun, Gabriel
    Maizel, Julien
    Liabeuf, Sophie
    Bodeau, Sandra
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2020, 1152 (1152):
  • [3] The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders
    Assem, Maryam
    Lando, Mathilde
    Grissi, Maria
    Kamel, Said
    Massy, Ziad A.
    Chillon, Jean-Marc
    Henaut, Lucie
    [J]. TOXINS, 2018, 10 (07)
  • [4] Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers
    Benedek, IH
    Joshi, AS
    Pieniaszek, HJ
    King, SYP
    Kornhauser, DM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (12) : 1181 - 1186
  • [5] PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY OF INDAPAMIDE
    CARUSO, FS
    SZABADI, RR
    VUKOVICH, RA
    [J]. AMERICAN HEART JOURNAL, 1983, 106 (01) : 212 - 220
  • [6] Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3
    Chioukh, Rym
    Noel-Hudson, Marie-Sophie
    Ribes, Sandy
    Fournier, Natalie
    Becquemont, Laurent
    Verstuyft, Celine
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (12) : 2041 - 2048
  • [7] Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein
    Chu, Xiao-Yan
    Bleasby, Kelly
    Yabut, Jocelyn
    Cai, Xiaoxin
    Chan, Grace Hoyee
    Hafey, Michael J.
    Xu, Shiyao
    Bergman, Arthur J.
    Braun, Matthew P.
    Dean, Dennis C.
    Evers, Raymond
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (02) : 673 - 683
  • [8] DAVIES DL, 1974, CLIN PHARMACOL THER, V15, P141
  • [9] Using binding competitors of albumin to promote the removal of protein-bound uremic toxins in hemodialysis: Hope or pipe dream?
    Florens, Nans
    Yi, Dan
    Juillard, Laurent
    Soulage, Christophe O.
    [J]. BIOCHIMIE, 2018, 144 : 1 - 8
  • [10] Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction
    Fujii, Hideki
    Goto, Shunsuke
    Fukagawa, Masafumi
    [J]. TOXINS, 2018, 10 (05):